Skip to content

Study · In vitro (cells) · 2002

3 results

Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue.

Crescioli C, Villari D, Forti G, Ferruzzi P, Petrone L, Vannelli GB, Adorini L, Salerno R, Serio M, Maggi M

Molecular and cellular endocrinology1 Dec 2002Cited by 12 (Europe PMC)

PMID12573816 (opens in a new tab)DOI10.1016/s0303-7207(02)00370-2 (opens in a new tab)PepBankPUB-12573816
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human BPH stromal cells, Des (1-3) IGF-I stimulated cell growth.

    In plain wordsIn cells from human benign prostate enlargement, Des (1-3) IGF-I stimulated cell growth.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseCell growth
    Study

    humann: not reported in source

    BPH stromal cells
    Outcome group
    Cell proliferation and differentiation · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that Des (1-3) insulin-like growth factor [Des (1-3) IGF-I], an IGF-I analogue, which does not bind to IGF-binding proteins, is a potent mitogen for BPH stromal cells via a dual mechanism: stimulation of cell growth and inhibition of apoptosis.
  2. 02LabIn vitro (cells)Mechanism

    In human BPH stromal cells, Des (1-3) IGF-I inhibited apoptosis.

    In plain wordsIn cells from human benign prostate enlargement, Des (1-3) IGF-I inhibited programmed cell death.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseApoptosis
    Study

    humann: not reported in source

    BPH stromal cells
    Outcome group
    Cell viability and death · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that Des (1-3) insulin-like growth factor [Des (1-3) IGF-I], an IGF-I analogue, which does not bind to IGF-binding proteins, is a potent mitogen for BPH stromal cells via a dual mechanism: stimulation of cell growth and inhibition of apoptosis.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 03LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Efficacy outcome

    In human BPH cells, vitamin D analogue (V) inhibited mitogenic activity of growth factors including Des (1-3) IGF-I.

    In plain wordsIn cells from human prostate tissue, vitamin D analogue (V) inhibited growth stimulation from growth factors including Des (1-3) IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseMitogenic activity inhibited by vitamin D analogue
    Study

    humann: not reported in source

    BPH stromal cells
    Outcome group
    Cell proliferation and differentiation · Reproductive and sexual health

    Source sentences

    Summary
    We also found analogue (V) not only inhibits the mitogenic activity of growth factors on BPH cells
    1 context sentence
    Summary · context
    We found that Des (1-3) insulin-like growth factor [Des (1-3) IGF-I], an IGF-I analogue, which does not bind to IGF-binding proteins, is a potent mitogen for BPH stromal cells via a dual mechanism: stimulation of cell growth and inhibition of apoptosis.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.